Omnigen is building a global research community.
Through our innovative Discover Me platform, Omnigen is integrating health and genetic data on 100,000s of people to help discover new ways to treat diseases and manage health and care.
We encourage everyone to participate in Discover Me, and especially individuals from diverse communities to make healthcare research relevant to everyone.
Working with our trusted partners, Omnigen can help to discover novel targets for new medicines and diagnostic tools. We can identify people that are more likely to benefit from treatments, design better clinical trials and refer participants to them, including for rare diseases.
We have created a robust privacy framework to ensure participant trust in our data management and sharing practices. We are compliant with GDPR and related laws.
All research is independently assessed and approved by government-recognised research ethics committees or institutional review boards to ensure our work is of the highest ethical standards.
Designing a secure, reliable data environment is a central part of our technology and we combine these robust privacy technologies with strong governance.
By partnering with healthcare providers and the wider public, we are:
Working within a transparent and ethical framework, and directly with care providers, Discover Me enables everyone to view accessible summaries of their health and care data.
An integrated healthcare and genetic data platform will help provide a framework to develop algorithms to improve patient care and services.
Creating a database of continually updated long-term patient health records along with genetic information will help provide opportunities to understand the causes and risk factors of many diseases.
The latest news and events from the team and our research initiatives at Omnigen.
02 Aug 2023
Omnigen Biodata is delighted to be part of a global team of scientists and researchers, who have discovered a genetic variant that may explain the naturally lower viral loads of HIV seen in some people of African ancestry. This is the first new genetic variant associated with HIV infection identified in almost 30 years. This discovery, reported in Nature, could help direct the development of new therapeutics and improve treatment options for those living with HIV. This work highlights the importance of conducting genetic research in diverse populations, including those of African ancestry.
21 Jun 2023
Omnigen Biodata is excited to announce the launch of the Discover Me South Africa study. This innovative study aims to enrol up to 100,000 individuals from the local population of Durban, South Africa. To enable this study, Omnigen Biodata is collaborating with the University of KwaZulu-Natal (UKZN), Inkosi Albert Luthuli Central Hospital (IALCH), the KwaZulu-Natal Department of Health, Regeneron Genetics Center, AstraZeneca, Roche, including Genentech, a member of the Roche Group, GSK, Pfizer and Alnylam.
01 Dec 2022
We are pleased to announce the relaunch of the Discover Me UK study. This is a nationwide research study working closely with healthcare organisations across the UK, including GP practices, to recruit 100,000 people. The study aims to recruit diverse communities across the UK, and link health and genetic information to help us better understand how diseases are caused and how they progress. And by equipping participants with insights into their health and ancestry information, people involved in the study are able to find out more about themselves as well as be informed on their own healthcare choices. Find out more at www.discovermestudy.com/dmuk.
Join our global research community today.
Discover Me is a nationwide research study looking at how health and genetic information can allow us to better understand disease.
By collecting this information from 100,000s of people, Discover Me aims to help us find out why diseases may affect some people more than others. This could help transform healthcare.
All participants in the Discover Me UK study are able to receive health insights and their genetic ancestry profile.
Register your interest in the study and contribute to the future of healthcare research today.
Omnigen is committed to building a discovery science program that is globally representative—enabling discovery, supporting communities, and building research capacity.
In collaboration with the University of KwaZulu-Natal and Inkosi Albert Luthuli Central Hospital and the KwaZulu-Natal Department of Health, the Discover Me South Africa study aims to recruit up to 100,000 individuals, and integrate their electronic health record and genetic data to help understand disease risk and progression, and improve patient care and management. All participants will receive access to their health data and become part of our global research community.
Omnigen's team has extensive academic and industry experience enabling innovation in real world data and genomics. We have diverse skills and experience spanning clinical research, technology, governance, and design.
Manjinder is a Professor of Population Health and Data Sciences at Imperial College London. He trained at King's College London, the London School of Hygiene and Tropical Medicine, and the University of Cambridge. He was also senior group leader at the Wellcome Sanger Institute between 2009 and 2019.
His academic research focuses on creating and interpreting health and genetic data and integrating technological advances at the population health level. As Omnigen's Founder, his work now centres on integrating real-world data, including electronic health records, and genomic resources in Europe, the Middle East, Asia and Africa.
We are a small health research and development start-up company based in Cambridge, UK. We are growing fast. If you share our values and approach to building biodata ethically and working with healthcare providers and the public, and have skills and passion to contribute, contact us at